The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Abstract
PURPOSE: The aim of the present study was to analyze the role of thymidylate synthase (TS; main cellular target of fluorouracil [FU]) and dihydropyrimidine dehydrogenase (DPD; rate-limiting enzyme of FU catabolism) in tumoral biopsies with respect to FU responsiveness. PATIENTS AND METHODS: This prospective study was conducted on 62 head and neck cancer patients (six stage II, 16 stage III, and 40 stage IV). All received first-line chemotherapy with biomodulated FU (5-day continuous infusion). Before treatment, a tumor biopsy and control biopsy (symmetrical nontumoral area) were obtained. Cytosolic TS and DPD activities were measured using radioenzymatic assays. RESULTS: DPD activity was detectable in all samples, without a significant difference between tumoral (median, 60 pmol/min/mg protein; range, 13 to 193) and nontumoral samples (median, 68 pmol/min/mg protein; range, 12 to 150). Tumoral TS and tumoral DPD were not significantly influenced by tumor localization or tumor staging. Among 52 tumors assessable for clinical response, we observed 46% complete responses (CRs), 33% partial responses (PRs), and 21% no responses (NRs). No relationship was demonstrated between TS activity and response to FU therapy. The comparison of tumoral DPD between complete responders and partial or nonresponders showed a trend toward significance (P = .06). In an attempt to reduce variability, we analyzed the tumoral/nontumoral DPD activity ratio; complete responders exhibited a significantly lower normalized DPD than partial or nonresponding patients (median, 0.86, 1.18, and 1.42 for CR, PR, and NR, respectively; CR v PR plus NR, P = .03). CONCLUSION: Although resistance to FU is multifactorial, the present clinical study suggests that FU catabolism in target cells is probably a determinant factor for FU responsiveness in cancer patients and justifies the clinical use of specific DPD inhibitors as FU biomodulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., & Hong, W. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280306 · Cited by 2,211
Metabolism and mechanism of action of 5-fluorouracil
Parker, W. B., & Cheng, Y. C. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90056-8 · Cited by 451
Harris, B., Song, R., Soong, S.-J., & Diasio, R. B. (1990) · PubMed · Cited by 441
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
Scanlon, K. J., Newman, E. M., Lu, Y., & Priest, D. G. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.23.8923 · Cited by 367
Enzymes of uracil catabolism in normal and neoplastic human tissues.
Naguib, F. N. M., el Kouni, M. H., & Cha, S. (1985) · PubMed · Cited by 277
Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270
Self-citationHorikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Volkenandt, M., Shea, L. C. C., Aigner, K., Gustavsson, B. G., Leichman, L., Frösing, R., & Ray, M. (1992) · PubMed · Cited by 242
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., & Allegra, C. J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.7.890 · Cited by 241
Johnston, P. G., Drake, J. C., Trepel, J. B., & Allegra, C. J. (1992) · PubMed · Cited by 226
Overview of Combined Modality Therapies for Head and Neck Cancer
Dimery, I. W., & Hong, W. K. (1993) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/85.2.95 · Cited by 210
Houghton, J. A., Maroda, S. J., Phillips, J. O., & Houghton, P. J. (1981) · PubMed · Cited by 194
Peters, G. J., Laurensse, E. J., LEYVA, A., Lankelma, J., & Pinedo, H. M. (1986) · PubMed · Cited by 193
Aschele, C., Sobrero, A. F., Faderan, M. A., & Bertino, J. R. (1992) · PubMed · Cited by 188
Shirasaka, T., Shimamoto, Y., Ohshimo, H., Saito, H., & Fukushima, M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685830 · Cited by 151
Sommadossi, J., Gewirtz, D. A., Diasio, R. B., Aubert, C., Cano, J. P., & Goldman, I. D. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34313-8 · Cited by 144
van der Wilt, C. L., Pinedo, H. M., Smid, K., & Peters, G. J. (1992) · PubMed · Cited by 118
Ho, D. H., Townsend, L. B., Luna, M. A., & Bodey, G. P. (1986) · PubMed · Cited by 114
Clinical relevance of biochemical modulation of 5-fluorouracil
Peter, G., & van Groeningen, C. J. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057994 · Cited by 109
Vokes, E. E., Schilsky, R. L., Weichselbaum, R. R., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.241 · Cited by 104
Cao, S., Rustum, Y. M., & Spector, T. (1994) · PubMed · Cited by 103
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase
Harris, B., Song, R., He, Y., Soong, S.-J., & Diasio, R. B. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90349-8 · Cited by 77
Etienne, M. C., Bernard, S., Fischel, J.-L., et al. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.88 · Cited by 43
Self-citationInhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil
Daher, G. C., Naguib, F. N. M., el Kouni, M. H., Zhano, R., Soong, S.-J., & Diasio, R. B. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90128-r · Cited by 15
Cited by
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 606
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
van Kuilenburg, A. B. P. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.12.004 · Cited by 488
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Metadata
- Authors
- Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., & Milano, G.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-07
- Volume
- 13
- Issue
- 7
- Pages
- 1663-1670
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1828890888
- Cited by
- 281
- References
- 23
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.